Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

47.75 USD +1.79 (+3.89%)
Official Closing Price Updated: 5:00 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Agios Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 – 
From GlobeNewswire News Releases
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
From GlobeNewswire News Releases
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
From GlobeNewswire News Releases
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR. 
From PR Newswire
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
From GlobeNewswire News Releases
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
From GlobeNewswire News Releases
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
From GlobeNewswire News Releases
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
From GlobeNewswire News Releases
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
From GlobeNewswire News Releases
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
From GlobeNewswire News Releases
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
From GlobeNewswire News Releases
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
From GlobeNewswire News Releases
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
From GlobeNewswire News Releases
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
From GlobeNewswire News Releases
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 
From GlobeNewswire News Releases
Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
From GlobeNewswire News Releases
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today... 
From PR Newswire
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
From GlobeNewswire News Releases
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020
From GlobeNewswire News Releases
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
From GlobeNewswire News Releases
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
From GlobeNewswire News Releases
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
From GlobeNewswire News Releases
Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study
From GlobeNewswire News Releases
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
From GlobeNewswire News Releases
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
From GlobeNewswire News Releases
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cho
From GlobeNewswire News Releases
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.